Table 2.

Pathology of EAE Mice Treated with IGF-1 during the Chronic Phase

Period of treatment	Day sampled	Treatment/control	Inflammation	Demyelination	Remyelination	Wallerian degeneration
25–39 dpt	38	Tx	1.7 ± 0.8	1.3 ± 1.0	0	0
		Con	2.6 ± 0.7	1.2 ± 1.0	0	0
	95	Tx	1.3 ± 0.5	1.1 ± 0.6	1.3 ± 0.5	0
		Con	2.2 ± 0.8	1.6 ± 0.2	1.8 ± 0.4	2.0 ± 0.9
30–44 dpt	53	Tx	2.5 ± 1.8	1.1 ± 0.9	2.0 ± 1	2.3 ± 0.5
		Con	2.0 ± 0.7	1.1 ± 0.8	1.4 ± 0.5	1.7 ± 0.4
41–55 dpt	60	Tx	2.1 ± 0.7	1.9 ± 0.7	1.3 ± 0.5	2.6 ± 0.5
		Con	2.2 ± 0.4	2.2 ± 1.2	1.3 ± 0.4	2.7 ± 0.7
65–79 dpt	93	Tx	2.6 ± 0.7	2.3 ± 0.5	1.8 ± 0.4	2.5 ± 0.5
		Con	2.2 ± 0.6	1.9 ± 0.9	1.3 ± 0.5	2.0 ± 0
78–92 dpt	171	Tx	2.2 ± 1.5	1.3 ± 1.0	1.7 ± 0.5	0
		Con	1.8 ± 0.8	1.7 ± 0.9	0	0